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Introduction
Growth of skeletal and cardiac muscles, like that of dividing cells, 
is largely dependent on signaling through the insulin–PI3K–Akt–
FoxO pathway. Conversely, the atrophy of specific muscles upon 
disuse or denervation and the systemic muscle wasting in fast-
ing and disease states (e.g., cancer cachexia, sepsis, and untreated 
diabetes) results from reduced activity of this pathway (Stitt et al., 
2004; Glass, 2010). This rapid loss of muscle mass results pri-
marily from the accelerated degradation of myofibrillar and sol-
uble proteins, but in most catabolic states (e.g., fasting), protein 
synthesis also decreases.
Development of these various types of atrophy requires the 
transcription of a common set of atrophy-related genes (“atro-
genes”; Lecker et al., 2004) by FoxO transcription factors, whose 
activation is sufficient to cause accelerated proteolysis and   
atrophy (Sandri et al., 2004). In atrophying muscles, multiple 
components of the ubiquitin-proteasome pathway, such as the 
muscle-specific ubiquitin ligases muscle RING-finger 1 (MuRF1) 
and Atrogin1/MAFbx (Bodine et al., 2001; Gomes et al., 2001), 
are induced, and their induction is essential for rapid wasting. 
Another ubiquitin ligase that appears to be critical for atrophy is 
Trim32 (tripartite motif containing protein 32; Cohen et al., 
2012). Like MuRF1, Trim32 contains a tripartite motif (RING; 
B-box; coiled-coil), but also has six NHL repeats with puta-
tive protein-binding properties (Slack and Ruvkun, 1998; Frosk   
et al., 2002), and mutations in the third repeat cause limb girdle 
muscular dystrophy 2H (LGMD-2H). We demonstrated that 
during muscle wasting, MuRF1 is essential for the ubiquitin-
dependent degradation of proteins comprising the thick filament 
(Cohen et al., 2009), whereas Trim32 catalyzes the disassembly 
and degradation of the desmin cytoskeleton, Z-band, and thin-
filament proteins, which are linked processes (Cohen et al., 
2012). Surprisingly, the down-regulation of Trim32 in muscle 
reduced not only the breakdown of these contractile and cyto-
skeletal proteins, but also the total loss of muscle mass upon 
fasting (Cohen et al., 2012). Therefore, Trim32 must have other 
critical substrates in muscle that accumulate upon Trim32 inhi-
bition  and  block  protein  breakdown  and/or  promote  protein 
A
ctivation of the PI3K–Akt–FoxO pathway induces 
cell  growth,  whereas  its  inhibition  reduces  cell 
survival and, in muscle, causes atrophy. Here, we 
report a novel mechanism that suppresses PI3K–Akt–FoxO 
signaling. Although skeletal muscle lacks desmosomes, it 
contains multiple desmosomal components, including plak-
oglobin. In normal muscle plakoglobin binds the insulin re-
ceptor and PI3K subunit p85 and promotes PI3K–Akt–FoxO 
signaling. During atrophy, however, its interaction with 
PI3K–p85 is reduced by the ubiquitin ligase Trim32 (tri-
partite motif containing protein 32). Inhibition of Trim32 
enhanced plakoglobin binding to PI3K–p85 and pro-
moted PI3K–Akt–FoxO signaling. Surprisingly, plakoglobin 
overexpression alone enhanced PI3K–Akt–FoxO signal-
ing. Furthermore, Trim32 inhibition in normal muscle in-
creased PI3K–Akt–FoxO signaling, enhanced glucose 
uptake, and induced fiber growth, whereas plakoglobin 
down-regulation reduced PI3K–Akt–FoxO signaling, de-
creased glucose uptake, and caused atrophy. Thus, by 
promoting plakoglobin–PI3K dissociation, Trim32 reduces 
PI3K–Akt–FoxO signaling in normal and atrophying mus-
cle. This mechanism probably contributes to insulin resis-
tance during fasting and catabolic diseases and perhaps 
to the myopathies and cardiomyopathies seen with Trim32 
and plakoglobin mutations.
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upon overexpression of proteins containing coiled-coil domains 
that  mediate  protein  interactions  and  multimerization. Thus, 
Trim32 seems to function in normal postnatal muscle to limit 
fiber growth, and suppression of its activity alone can induce 
muscle hypertrophy.
Plakoglobin is present in skeletal muscle
These findings and our prior ones (Cohen et al., 2012) imply that 
certain Trim32 substrates accumulate upon its down-regulation 
and reduce atrophy or induce growth. Using immobilized GST-
Trim32 and mass spectrometry (Cohen et al., 2012), we identi-
fied several Trim32 substrates in muscle extracts (Cohen et al., 
2012) that were bound and could be ubiquitinated by Trim32, 
including thin-filament and Z-band components, plus the cyto-
skeletal protein desmin. Surprisingly, the immobilized Trim32 
also bound plakoglobin, which, in other tissues, is a component 
of the desmosome complex. Its presence was unexpected be-
cause there had been no prior reports of desmosomes or its com-
ponents in skeletal muscle. During fasting, however, Trim32 
synthesis and growth. The present studies were undertaken to test 
this intriguing hypothesis and to identify the proposed growth-
regulatory factor whose function is controlled by Trim32.
These studies have identified a novel protein in skeletal 
muscle, plakoglobin, whose function is regulated by Trim32. 
Plakoglobin is a component of the desmosome adhesion com-
plex that is prominent in tissues that must withstand mechanical 
stress, especially cardiomyocytes and epithelia (Buxton et al., 
1993; Koch and Franke, 1994; Gumbiner, 1996, 2005). In epi-
thelia, plakoglobin regulates signaling pathways (e.g., by Wnt) 
that control cell motility (Jamora and Fuchs, 2002), growth, and 
differentiation (Calautti et al., 2005). We show here that plako-
globin is of prime importance in regulating muscle size because 
it binds to the insulin receptor and enhances the activity of the 
PI3K–Akt–FoxO pathway. Activation of this pathway by IGF-I 
or insulin promotes overall protein synthesis and inhibits pro-
tein degradation (Sacheck et al., 2004; Glass, 2005) by both   
autophagy and the ubiquitin-proteasome pathway (Mammucari   
et al., 2007; Zhao et al., 2007). During fasting and in disease 
states, when IGF-I and insulin levels are low, PI3K–Akt–FoxO 
signaling decreases, and proteolysis increases largely via FoxO-
mediated expression of the atrogene program (Sandri et al., 
2004). Also, in untreated diabetes, sepsis, and cancer cachexia 
(Zhou et al., 2010), impaired signaling through this pathway 
can cause severe muscle wasting, which can be inhibited by the 
activation of PI3K–Akt–FoxO signaling (Wang et al., 2006). 
We demonstrate here for the first time that plakoglobin is an im-
portant constituent of skeletal muscle where it binds to both the 
insulin receptor and the p85 regulatory subunit of PI3K to en-
hance signaling by the PI3K–Akt–FoxO cascade. Surprisingly, 
changes in plakoglobin levels alone influence PI3K–Akt–FoxO 
pathway in muscle and thereby can cause muscle growth or 
block atrophy. Thus, Trim32 functions as a novel inhibitor of 
PI3K–Akt–FoxO  signaling  by  regulating  plakoglobin–PI3K 
binding, which is important for activation of this pathway in 
muscle and probably most tissues.
Results
Trim32 inhibition induces normal  
muscle growth
Because down-regulation of Trim32 reduces muscle atrophy 
(Cohen et al., 2012), we determined whether it also affects the 
mass of normal muscles by electroporation into tibialis anterior 
(TA) muscle of a dominant-negative Trim32 (Trim32-DN), which 
lacks the catalytic RING domain and is fused to GFP to identify 
the transfected fibers (Kano et al., 2008). Overexpression of 
Trim32-DN for 6 d resulted in a 15% increase in weight over 
that of muscles electroporated with a control vector (Fig. 1 A). 
Because not all fibers were transfected, the growth induced by 
Trim32 inhibition must be even greater. In fact, the mean cross-
sectional area of 500 fibers expressing Trim32-DN was much 
larger than that of 500 nontransfected ones (Fig. 1 B). The 
Trim32-DN inhibits the endogenous Trim32, although some of 
the overexpressed Trim32 seemed to form intracellular aggre-
gates (Locke et al., 2009; Ichimura et al., 2013), as often occurs 
Figure 1.  Inhibition of Trim32 in normal muscle induces rapid growth. TA 
muscles were electroporated with shLacz or Trim32-DN and analyzed 6 d 
later. (A) Mean weights of Trim32-DN–expressing muscles are presented 
as percent increase versus control. n = 10; *, P < 0.05. (B) Cross-sectional 
areas of 500 fibers transfected with GFP-Trim32-DN (black vs. 500 non-
transfected fibers [open] in the same muscle. n = 6. Laminin staining is in 
red. Bar, 15 µm.749 Trim32 reduces PI3K–Akt–FoxO signaling during muscle atrophy • Cohen et al.
(Fig. 3 A). Thus, during fasting, Trim32 reduces the association of 
plakoglobin with p85–PI3K. In addition, we determined if these 
interactions were unique to skeletal muscle or whether plakoglobin 
might regulate this signaling pathway generally. Similar inter-
actions between p85–PI3K and plakoglobin were demonstrated by 
coimmunoprecipitation in the heart and liver (Fig. 3 B), and thus 
are probably functioning in most, perhaps all, cells.
Further studies determined whether the interaction of plak-
oglobin with p85–PI3K in fact influences PI3K–Akt–FoxO sig-
naling. By two days after food deprivation, phosphorylation of 
PI3K, Akt, and its target FoxO3, as well as the mTOR target S6K 
was markedly reduced (Fig. 3 C; Sandri et al., 2004; Stitt et al., 
2004). However, down-regulation of Trim32 almost completely 
blocked this response to fasting. In fact, the levels of phosphory-
lated PI3K, Akt, FoxO3, and S6K were similar to those in mus-
cles from fed mice (Fig. 3 C). Normally during fasting, FoxO is 
activated (dephosphorylated) and stimulates the expression of a 
set of atrophy-related genes, including the ubiquitin ligases 
MuRF1 and Atrogin1, which are essential for rapid fiber atrophy 
(Fig. 3 D; Bodine et al., 2001; Gomes et al., 2001). However, 
Trim32 inhibition by overexpression of the Trim32-DN resulted 
in a marked decrease in MuRF1 and Atrogin1 expression in the 
TA muscles during fasting (Fig. 3 D). This inhibition of atrogene 
expression during fasting together with the maintenance of nor-
mal PI3K–Akt–mTOR signaling can account for the dramatic 
blockage of muscle wasting observed previously (Cohen et al., 
2012). Thus, during fasting, Trim32 function is critical in causing 
the reduction in PI3K–Akt–FoxO signaling that triggers the de-
crease in protein synthesis, the FoxO-mediated expression of the 
atrogene program, and muscle wasting (Cohen et al., 2012).
Plakoglobin mediates the effects of Trim32 
on PI3K–Akt signaling
To learn whether plakoglobin influences PI3K–Akt–FoxO sig-
naling, we down-regulated plakoglobin by electroporation of 
shRNA (shJUP) into normal muscle (Fig. 4 A). The resulting 
fall in plakoglobin led to decreased phosphorylation of PI3K, 
Akt, and FoxO3. Thus, plakoglobin is required for normal sig-
naling through the PI3K–Akt–FoxO pathway. Accordingly, 
when plakoglobin was down-regulated with shRNA in normal 
muscle for 6 d, atrophy of the muscle fibers became evident 
(Fig. 4 B). The mean cross-sectional area of 500 fibers express-
ing shJUP (and GFP to identify transfected fibers) was smaller 
than that of 500 nontransfected fibers (Fig. 4 B). Although ex-
pressing the Trim32-DN prevented the decrease in PI3K–Akt–
FoxO signaling in the atrophying muscles, this effect was 
markedly attenuated by simultaneously down-regulating plako-
globin (Fig. 4 C). Thus, plakoglobin appears critical for the 
Trim32-induced reduction in phosphorylation of PI3K, Akt, and 
FOXO3 (Fig. 4 C).
In addition to regulating cell size and protein balance, the 
PI3K–Akt–FoxO pathway also mediates insulin’s stimulation 
of glucose uptake into muscle and adipose tissue. As predicted, 
plakoglobin down-regulation in myoblasts reduced the stimulation 
by insulin of glucose uptake (Fig. 4 D). Although plakoglobin is 
clearly an important regulator of this process, overexpression of 
does not significantly reduce plakoglobin content (Fig. S1) or 
stability (see Fig. 3 A), but clearly alters its function, as discussed 
in Fig. 3.
In epithelial cells, binding of PI3K to plakoglobin was 
proposed  to  enhance  PI3K–Akt  signaling  (Woodfield  et  al., 
2001; Calautti et al., 2005). Because this pathway is the primary 
regulator of the mass of muscle and probably all eukaryotic 
cells, we investigated whether its activity is affected by the lev-
els of plakoglobin and Trim32. However, it was important initially 
to confirm that plakoglobin is actually present in the muscle   
fibers and not endothelial cells. Therefore, we analyzed its spatial 
distribution in normal TA by immunofluorescence staining of 
paraffin-embedded cross and longitudinal sections. In epithe-
lia, plakoglobin has a punctate distribution throughout the cell 
(Näthke et al., 1994; Chen et al., 2002). We found a similar spot-
like distribution of plakoglobin within the muscle fibers, and in 
the plane of the fiber membrane (Fig. 2 A). Thus, this protein, 
unlike myofibrillar components or desmin (Cohen et al., 2012), 
did not show a specific periodic distribution along the sarco-
mere. A similar diffuse distribution of plakoglobin was observed 
in C2C12 myotubes (Fig. 2 A).
Furthermore, the presence of this protein in both the soluble 
phase and the muscle membrane was confirmed biochemically 
by fractionation of TA muscle (Fig. 2 B). To further support these 
findings, we performed immunofluorescence staining of muscle 
cross sections with plakoglobin and dystrophin antibodies. As 
shown in Fig. 2 C, plakoglobin colocalized with the membrane 
protein dystrophin (Fig. 2 C). Interestingly, plakoglobin also co-
localized with the muscle stem cell marker, the transcription fac-
tor Pax 7, indicating that plakoglobin is also present in satellite 
cells (Fig. 2 D). The finding of plakoglobin in satellite cells is 
consistent with its presence in cultured myoblasts (see Fig. 4 D) 
and with its playing an important role in the development of stri-
ated muscle (Ruiz et al., 1996; Asimaki et al., 2007).
Trim32 knockdown in fasting increases 
PI3K–Akt–FoxO signaling
Because plakoglobin in muscle extracts was bound to Trim32, 
we determined whether it is lost during fasting and the role of 
Trim32 in this process. Interestingly, whether or not Trim32 
was down-regulated by electroporation, the muscle content of 
plakoglobin did not change during fasting from that in the fed 
control (which expressed a control shRNA; Fig. 3 A). Thus, 
during fasting, plakoglobin is not directed for degradation by 
Trim32, and the interaction between Trim32 and plakoglobin is 
probably mediated by additional associated proteins.
To determine whether plakoglobin influences the activity 
of the PI3K–Akt–FoxO pathway, as had been suggested in ke-
ratinocytes (Calautti et al., 2005), we investigated whether plak-
oglobin interacts with p85–PI3K in muscle. Plakoglobin could 
be coprecipitated with p85–PI3K from muscles of the fed mice, 
but not during fasting (Fig. 3 A), where PI3K–Akt–FoxO sig-
naling was reduced (Fig. 3 C). This change in plakoglobin asso-
ciation seemed to result from Trim32 function because inhibition 
of Trim32 during fasting by electroporation of Trim32-DN re-
sulted in a greater association of plakoglobin with p85–PI3K JCB • VOLUME 204 • NUMBER 5 • 2014   750
Figure 2.  Plakoglobin is present in skeletal muscle. (A) Paraffin-embedded longitudinal and cross sections of TA muscles from fed mice (top; bar, 20 µm),   
and C2C12 myotubes (bottom; bar, 15 µm) were stained with anti-plakoglobin. (B) Plakoglobin is present in the cytosolic and membrane fractions of 
muscle. 0.25% of membrane fraction and 0.01% of cytosolic fraction were analyzed by immunoblotting. GAPDH serves as a cytosolic marker. (C) Plako-
globin is present on the muscle membrane. Paraffin-embedded cross sections of normal TA muscles were stained with anti-plakoglobin and anti-dystrophin. 
Bar, 20 µm. The box on the right indicates an area of magnification (bar, 4.3 µm). (D) Plakoglobin is present in satellite cells. Paraffin–embedded cross 
sections of normal TA muscles were stained with anti-plakoglobin and anti-pax7 antibodies. Bar, 12 µm.751 Trim32 reduces PI3K–Akt–FoxO signaling during muscle atrophy • Cohen et al.
plakoglobin from normal muscle. Interestingly, during fast-
ing, plakoglobin remained associated with the insulin receptor   
(Fig. 4 E), even when Trim32 was inhibited by electroporation 
of Trim32-DN (Fig. 4 E). Plakoglobin thus binds to the insulin 
receptor and seems to serve as a key component in its inter-
actions with and activation of PI3K. This interaction has been 
confirmed in a reciprocal experiment with both normal and   
atrophying muscles where immunoprecipitation of the insu-
lin receptor also brought down plakoglobin (Fig. 4 E). Similar   
plakoglobin in normal myoblasts did not further stimulate this 
process (Fig. 4 D). Cytochalasin B is a cell-permeable myco-
toxin that competitively inhibits glucose transport into cells and 
was used here to evaluate specifically regulated glucose up-
take (Ebstensen and Plagemann, 1972). To test if plakoglobin 
mediates insulin-dependent glucose uptake by interacting with 
the insulin receptor and activating PI3K–Akt–FoxO signaling, 
we immunoprecipitated plakoglobin from normal and atrophy-
ing muscles. The insulin receptor coprecipitated together with   
Figure 3.  Trim32 down-regulation during fasting enhances plakoglobin binding to PI3K–p85 and PI3K–Akt–FoxO signaling. (A) During fasting, inhibi-
tion of Trim32 increases the interaction of plakoglobin with p85–PI3K. p85–PI3K was immunoprecipitated from the soluble fraction of muscles expressing 
shLacz or Trim32-DN from fed or fasted mice. Precipitates were analyzed by immunoblotting. Black lines indicate the removal of intervening lanes for 
presentation purposes. (B) Plakoglobin and p85–PI3K interact in heart and liver. p85–PI3K was immunoprecipitated from the soluble fraction of heart and 
liver from fed mice and analyzed by immunoblotting. The lines connecting the two bottom panels show the input lane for the heart sample that was used for 
two immunoprecipitation reactions using IgG (for control) or PI3K antibody. (C) During fasting, down-regulation of Trim32 increases PI3K–Akt–FoxO signal-
ing. Soluble fractions of normal and atrophying muscles expressing shLacz or shTrim32 were analyzed by SDS-PAGE and immunoblot. Black lines indicate 
the removal of intervening lanes for presentation purposes. (D) Inhibition of Trim32 reduces MuRF1 and Atrogin1 expression during fasting. Quantitative   
RT-PCR of mRNA preparations from atrophying and control muscles expressing shLacz or Trim32-DN using primers for MuRF1 and Atrogin1. Data are 
plotted as the mean fold change relative to fed control. n = 4. *, P < 0.05 vs. shLacz in fed. #, P < 0.05 vs. shLacz in fasting.JCB • VOLUME 204 • NUMBER 5 • 2014   752
Figure 4.  Plakoglobin down-regulation reduces PI3K–Akt–FoxO signaling, glucose uptake, and fiber size. (A) Plakoglobin knockdown with shJUP results 
in reduced PI3K–Akt–FoxO signaling. Normal TA muscles were transfected with shLacz or plakoglobin shRNA (shJUP), and soluble extracts were analyzed 
by SDS-PAGE and immunoblot. Black lines indicate the removal of intervening lanes for presentation purposes. (B) Down-regulation of plakoglobin induces 
muscle atrophy. Cross-sectional areas of 500 fibers transfected with shJUP (that express GFP, black bars) vs. 500 nontransfected fibers (open bars) in 
the same muscle. n = 6. (C) During fasting, down-regulation of plakoglobin reduces the increase in PI3K–Akt–FoxO signaling induced by Trim32-DN. 
Soluble fractions of muscles expressing shLacz alone, Trim32-DN together with shLacz, or Trim32-DN together with shJUP were analyzed by SDS-PAGE 
and immunoblot. Black lines indicate the removal of intervening lanes for presentation purposes. (D) Plakoglobin down-regulation in C2C12 myoblasts 753 Trim32 reduces PI3K–Akt–FoxO signaling during muscle atrophy • Cohen et al.
whereas  increasing  plakoglobin  levels  stimulates  this  process 
(Figs. 4 G and 5 B), Trim32-mediated inhibition of plakoglobin 
function may also contribute to insulin resistance in various cata-
bolic states (e.g., diabetes, metabolic syndrome, or sepsis). Con-
sequently, Trim32 may represent a new therapeutic target to block 
muscle wasting and the insulin resistance characteristic of many 
disease states (e.g., cancer cachexia, sepsis, and renal failure).
In  normal  muscle,  plakoglobin  down-regulation  reduces 
PI3K–Akt–FoxO signaling and causes atrophy (Fig. 4, A and B), 
whereas inhibiting Trim32 increases plakoglobin binding to 
PI3K–p85, enhances PI3K–Akt–FoxO phosphorylation, and in-
duces fiber hypertrophy (Figs.1 and 5). Thus, in addition to being 
critical in atrophy, Trim32 activity also limits the growth of nor-
mal muscle (Fig. 6). Moreover, Trim32 and plakoglobin probably 
serve similar regulatory roles in controlling the growth of other 
cells because both are expressed in most, if not all, tissues (Cowin 
et al., 1986; Frosk et al., 2002). In fact, plakoglobin has been shown 
to be an important regulator of epithelial growth (Venkiteswaran   
et al., 2002), and as shown here, it binds p85–PI3K in heart and 
liver (Figs. 3 B and 4 F), as it does in skeletal muscle (Figs. 3 A 
and 5 C). Interestingly, the close homologue of plakoglobin,   
-catenin, can also bind PI3K and enhance PI3K–Akt–FoxO sig-
naling (Woodfield et al., 2001). Moreover, -catenin was reported 
to decrease during atrophy induced by dexamethasone and to 
accumulate during hypertrophy (Schakman et al., 2008). Plako-
globin and -catenin can function together in regulating gene 
transcription (Zhurinsky et al., 2000a,b; Winn et al., 2002;   
Armstrong et al., 2006; Li et al., 2011), and possibly -catenin 
may also be regulated by Trim32.
Because Trim32 is not induced during fasting, its activity 
may be regulated by post-translational modifications of its sub-
strates, as we previously demonstrated for desmin (Cohen et al., 
2012), or by modifications of Trim32 itself, as has been shown 
to occur in other tissues (Dephoure et al., 2008; Ichimura et al., 
2013). Here we show that Trim32 activity promotes the dis-
association of the plakoglobin–PI3K complex and thereby inhib-
its PI3K–Akt signaling. Even though Trim32, when purified, 
can weakly ubiquitinate plakoglobin (unpublished data), and 
though it seems to affect plakoglobin stability in normal muscle 
(Fig. 5 A), plakoglobin content does not fall in fasting (Fig. 3 A). 
Thus,  in  the  atrophying  muscles,  Trim32  does  not  promote 
plakoglobin–PI3K dissociation by enhancing plakoglobin deg-
radation. Perhaps Trim32 promotes proteasomal degradation of 
an additional protein that is essential for the plakoglobin–PI3K 
complex, and that, like desmin, may be phosphorylated during 
interactions between plakoglobin and the insulin receptor were 
also observed in heart and liver (Fig. 4 F), suggesting that, in many 
tissues (perhaps all), plakoglobin functions to regulate insulin-
dependent activation of PI3K.
Together, these observations suggested that increasing the 
level of plakoglobin during fasting should lead to greater activ-
ity of the insulin receptor and PI3K–Akt–FoxO pathway. Accord-
ingly, during fasting, overexpression of GFP-tagged plakoglobin 
(which showed a similar distribution as did the endogenous pro-
tein; Fig. S2) alone enhanced phosphorylation of the insulin recep-
tor (at Y1361), activation of PI3K–Akt–FoxO signaling (Fig. 4 G), 
and reduced MuRF1 and Atrogin1 expression (Fig. 4 H). Thus, 
the Trim32-dependent inhibition of plakoglobin function is a 
key new step in the reduction in PI3K–Akt–FoxO signaling in 
low-insulin states.
Trim32 inhibition enhances PI3K–Akt–FoxO 
signaling in normal muscle
In light of these findings during fasting, we determined whether 
Trim32 may also influence muscle mass (Fig. 1) in the fed state 
by regulating PI3K–Akt–FoxO activity. After electroporation of 
the Trim32-DN or shTrim32 into normal TA for 6 d, phosphory-
lation of PI3K, Akt, and FOXO increased (Fig. 5 A). The levels 
of mTOR targets pS6K and p704E-BP1 were also increased 
(Fig. 5 A), indicating stimulation of mTOR by the inhibition of 
Trim32. Accordingly, transfection of Trim32-DN into C2C12 
myoblasts enhanced insulin-dependent glucose uptake above 
the levels in cells expressing a control plasmid (Fig. 5 B), and 
inhibition of Trim32 in normal muscle increased the association 
of plakoglobin with PI3K–p85 (Fig. 5 C). Thus, the growth- 
promoting effects of Trim32-DN are most probably due to en-
hanced PI3K–Akt–mTOR signaling. It is noteworthy that Trim32 
overexpression in normal muscle does not by itself alter PI3K–
Akt–FoxO signaling, glucose uptake, or fiber size (Fig. 5 B; 
Fig. S3). Therefore, an additional signal beyond Trim32 expres-
sion is probably required to decrease plakoglobin function, per-
haps phosphorylation of plakoglobin (Woodfield et al., 2001; 
Calautti et al., 2005).
Discussion
These studies have uncovered a novel mechanism regulating the 
PI3K–Akt–FoxO pathway that involves the desmosomal compo-
nent plakoglobin and the ubiquitin ligase, Trim32 (Fig. 6). Because 
decreasing plakoglobin content reduces glucose uptake (Fig. 4 D), 
reduces insulin-induced glucose uptake. [
3H]2-deoxy-d-glucose uptake (cpm) was measured in C2C12 myoblasts expressing shLacz, shJUP, or plakoglobin. 
Cytochalasin B is a competitive inhibitor of regulated glucose transport into cells. To determine the insulin-dependent glucose uptake, the values measured 
in the presence of 20 µM cytochalasin B were subtracted from the total uptake. n = 3, *, P < 0.05 vs. shLacz; #, P < 0.005 vs. shLacz. (E) Plakoglobin 
associates with the insulin receptor in normal and atrophying muscles. Plakoglobin (top) or insulin receptor (bottom) were immunoprecipitated from the 
soluble fraction of muscles expressing shLacz or Trim32-DN from fed or fasted mice. Precipitates were then analyzed by immunoblotting for insulin receptor 
and plakoglobin, as indicated. (F) Plakoglobin associates with insulin receptor in heart and liver. Plakoglobin was immunoprecipitated from the soluble 
fraction of heart and liver from fed mice and analyzed by immunoblotting. (G) During fasting, overexpression of plakoglobin alone activates insulin recep-
tor and enhances PI3K–Akt–FoxO signaling. Soluble fractions of normal and atrophying muscles expressing shLacz or GFP-plakoglobin were analyzed by 
SDS-PAGE and immunoblot. Black lines indicate the removal of intervening lanes for presentation purposes. (H) Overexpression of plakoglobin reduces 
MuRF1 and Atrogin1 expression during fasting. Quantitative RT-PCR of mRNA preparations from atrophying and control muscles expressing shLacz or 
GFP-plakoglobin using primers for MuRF1 and Atrogin1 (and GAPDH for reference). Data are plotted as the mean fold change relative to fed control. n = 4. 
*, P < 0.05 vs. shLacz in fed. #, P < 0.05 vs. shLacz in fasting.
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essential for its association with the insulin receptor and per-
haps for it to serve as a docking site for PI3K. In any case, this 
selective accumulation of plakoglobin led to increased phos-
phorylation of the insulin receptor and activity of the PI3K–Akt–
FoxO pathway (Fig. 4 G).
To our knowledge, this study also provides the first evi-
dence for the presence of the desmosomal component plako-
globin in skeletal muscle. In these and related studies, we also 
found that other components of the desmosomal complex, such 
as desmoplakin, are also present within muscle fibers (Fig. S4), 
although desmoplakin levels, unlike plakoglobin’s, did not alter 
PI3K–Akt–FoxO signaling (Fig. S4 A). In the heart, plako-
globin is a component of the adhesion complex, i.e., “desmo-
somes,” which are localized in the intercalated discs that link 
adjacent cardiomyocytes. Mice lacking plakoglobin tend to die 
early from cardiac rupture (Ruiz et al., 1996), and in humans, 
mutations in plakoglobin (Asimaki et al., 2007) or the six other 
atrophy (Cohen et al., 2012), so as to enhance its ubiquitination 
by Trim32. Alternatively, during fasting, ubiquitination of plak-
oglobin may occur but lead to p97-mediated dissociation of the 
plakoglobin–PI3K  complex  (Piccirillo  and  Goldberg,  2012). 
Clearly, the exact mode of regulation of Trim32 activity and the 
mechanism by which it catalyzes plakoglobin–PI3K dissocia-
tion are very important questions for future research.
It is noteworthy, however, that Trim32 overexpression by 
itself is not sufficient to reduce PI3K–Akt–FoxO activity or to 
cause atrophy (Fig. S3). Thus, the increase in PI3K–Akt–FoxO 
signaling with Trim32 down-regulation must involve an addi-
tional signal, such as plakoglobin phosphorylation, which has 
been reported (Woodfield et al., 2001; Calautti et al., 2005). Ac-
cordingly, we recently showed that ubiquitination of desmin by 
Trim32  during  fasting  also  requires  desmin  phosphorylation 
(Cohen et al., 2012). In normal muscle and during fasting, if 
Trim32 is inhibited, phosphorylation of plakoglobin may be   
Figure  5.  Trim32  inhibition  in  normal  muscle  increases  PI3K–Akt–FoxO  activity  and  glucose  uptake.  (A)  Down-regulation  of  Trim32  increases   
PI3K–Akt–FoxO and mTOR activity. (Left) Soluble fractions of normal TA muscles expressing shLacz, Trim32-DN (top), or shTrim32 (bottom) were analyzed 
by SDS-PAGE and immunoblot. The black line in the P-S6K panel indicates the removal of intervening lanes for presentation purposes. (Right) Densito-
metric measurement of band intensity in the presented blots. n = 3. (B) Trim32 inhibition in C2C12 myoblasts increases insulin-induced glucose uptake.   
[
3H]2-deoxy-d-glucose uptake was measured in C2C12 myoblasts expressing shLacz, Trim32, or Trim32-DN, as in Fig. 4 D. Cytochalasin B is a competi-
tive inhibitor of regulated glucose transport into cells. n = 3; *, P < 0.005 vs. shLacz; #, P < 0.005 vs. shLacz. (C) Inhibition of Trim32 in normal muscle 
enhances the interaction of plakoglobin with p85–PI3K. p85–PI3K was immunoprecipitated from the soluble fraction of normal muscles expressing shLacz 
or Trim32-DN. Precipitates were analyzed by immunoblotting. Black lines indicate the removal of intervening lanes for presentation purposes.755 Trim32 reduces PI3K–Akt–FoxO signaling during muscle atrophy • Cohen et al.
compensatory responses. The ability of these Trim32-deficient 
muscles to undergo atrophy suggests that additional ubiquitin 
ligases may replace Trim32 in its many regulatory roles. (In fact, 
our  prior  observations  had  suggested  that  alternative  ligases 
may also function in atrophy (Cohen et al., 2012)).
Conversely, expression of Trim32 rises in multiple dis-
eases, including the brains of Alzheimer’s patients (Yokota et al., 
2006), psoriasis lesions (Liu et al., 2010), and various cancers, 
where it enhances invasion and metastasis (Horn et al., 2004; 
Kano et al., 2008). These effects may also involve Trim32-
mediated regulation of plakoglobin stability or function because 
the loss of plakoglobin reduces cell adhesion and increases cell 
migration and invasion (Yin et al., 2005; Kundu et al., 2008; 
Gosavi et al., 2011).
Together, these observations indicate close coupling be-
tween changes in cytoskeletal and myofibrillar components 
during atrophy (Cohen et al., 2012) and the cell’s major growth 
regulatory system. This coupling could be important in other 
pathological states (Fig. 6). During atrophy, Trim32 catalyzes 
the ubiquitination and disassembly of the desmin cytoskeleton, 
which is coupled to the destruction of proteins comprising the 
thin filament and Z-band (Cohen et al., 2012). If desmin fila-
ments in skeletal muscle are also linked to plakoglobin (and 
other desmosomal proteins), as they are in the heart (Smith and 
Fuchs, 1998), then perturbation of plakoglobin function during 
atrophy, in addition to reducing PI3K–Akt–FoxO signaling, 
may be an early event leading to the disruption of the cytoskel-
eton and thereby to disassembly of thin filaments.
Materials and methods
In vivo transfection
Animal experiments were conducted according to the ethical guidelines of 
the National Institutes of Health Guide for the Care and Use of Laboratory 
Animals. Animal care was provided by specialized personnel in the Institu-
tional Animal Care facility. Experiments were performed in adult CD-1 
male mice (27–28 g). In vivo electroporation was performed by the injection 
genes encoding desmosomal proteins (Herren et al., 2009) re-
sult in cardiac arrhythmia (Asimaki et al., 2007), reduced con-
tractility, and cardiac failure (i.e., the syndrome of “arrhythmogenic 
right ventricular cardiomyopathy/dysplasia”). Perhaps these 
pathological sequelae may be due in part to altered signaling 
through the PI3K–Akt–FoxO pathway. By reducing the function 
of plakoglobin or perhaps other desmosomal components in the 
heart, Trim32 is also likely to have important physiological or 
pathological effects. However, in skeletal muscle, plakoglobin 
does not seem to form the “classic” desmosomes, although this 
protein is clearly present on the surface membrane (Fig. 2) and 
can be immunoprecipitated together with insulin receptor, PI3K, 
and Akt (Figs. 3 A and 4 E), as well as other components of des-
mosomes (Fig. S4 B). However, unlike dystrophin, plakoglobin 
does not seem to be evenly distributed along the muscle mem-
brane, and instead accumulates in certain regions, presumably by 
binding to specific receptors to stimulate signaling pathways or to 
promote cell–cell contacts. In addition to causing limb-girdle 
muscular dystrophy, Trim32 mutations can lead to Bardet-Biedl 
syndrome, which is characterized by cardiac hypertrophy and   
dilated cardiomyopathy (Elbedour et al., 1994). The present   
findings would predict that a deficiency of Trim32 could lead to 
excessive tissue growth and possibly inappropriate activation of 
PI3K–Akt–FoxO signaling.
Surprisingly, Spencer and colleagues recently described a 
Trim32-null mouse that exhibited multiple defects, including 
mild myopathies, neurogenic defects, cellular disorganization, 
and reduced muscle growth and body size (Kudryashova et al., 
2011, 2012). Nevertheless, upon fasting or disuse (Kudryashova 
et al., 2012), muscles from these mice atrophy to a similar ex-
tent, as in wild-type mice. These surprising observations differ 
markedly from the present findings on the effects of selective 
down-regulation of Trim32 in adult muscle or myotubes. Pre-
sumably, the complete deficiency of Trim32 in all cells during 
development causes multiple systemic defects and elicits multiple 
Figure 6.  Proposed new mechanism for regu-
lation of PI3K–Akt–FoxO pathway by Trim32. 
By  promoting  plakoglobin  dissociation  from 
PI3K–p85,  Trim32  reduces  PI3K–Akt–FoxO 
signaling  in  normal  and  atrophying  muscle 
and regulates growth. In addition to its role 
in myofibril breakdown during fasting (Cohen   
et al., 2012), Trim32 also functions as a novel 
inhibitor  of  PI3K–Akt–FoxO  signaling.  Be-
cause Trim32 and plakoglobin are expressed 
in  most  tissues  (Cowin  et  al.,  1986;  Frosk   
et al., 2002), they probably serve similar roles 
in  regulating  the  growth  of  other  cells.  This 
novel mechanism probably contributes to the 
insulin resistance during fasting and catabolic 
diseases (e.g., diabetes, sepsis), and perhaps 
to the myopathies and cardiomyopathies seen 
with Trim32 and plakoglobin mutations.JCB • VOLUME 204 • NUMBER 5 • 2014   756
1:5 dilution of pax7 antibody (supernatant), and 1:1,000 dilution of Alexa 
Fluor 555– or 647–conjugated secondary antibody were used. Images 
were collected at room temperature using an upright fluorescent micro-
scope (model 80i; Nikon), with Plan Apochromat 60× (Fig. 2 C) or 100× 
(Fig. 2 D) objective lenses, a 545/30 excitation filter, and 620/60 emis-
sion filter (Alexa Fluor 555); a 620/60 excitation filter and 700/75 emis-
sion filter (Alexa Fluor 647); a cooled CCD camera (ORCA-R2; Hamamatsu 
Photonics), and MetaMorph 7 software. In Fig. S2, a vector encoding GFP-
plakoglobin was electroporated into TA of adult wild-type mouse for 6 d. 
Muscle cross sections were embedded in paraffin and images were col-
lected at room temperature using an upright epifluorescence microscope 
(model 80i; Nikon) with a Plan Fluor 40× 1.4 NA objective lens, a 480/40 
excitation filter and 535/50 emission filter, and a cooled CCD camera 
(model C8484-03; Hamamatsu Photonics).
In Fig. 2 A, C2C12 cells were plated on a glass-bottom 12-well plate 
(P12G-1.5-14-F; MatTek Corporation), which was coated with 5 ug/ml fibro-
nectin (f1141; Sigma-Aldrich). Cells were differentiated into myotubes and 
then fixed in 4% PFA for 15 min at room temperature. After 15 min of block-
ing in 50 mg/ml BSA/TBS-T, immunofluorescence analysis was performed 
using a 1:50 dilution of plakoglobin antibody and 1:1,000 dilution of Alexa 
Fluor 555–conjugated secondary antibody, all diluted in blocking solution. 
Images were collected at room temperature using an inverted motorized mi-
croscope (model Ti-E; Nikon) with a Plan Apochromat 1.4 NA 60× objective 
lens, a 545/30 excitation filter and 620/60 emission filter (Alexa Fluor 
555), a cooled CCD camera (ORCA-R2; Hamamatsu Photonics), and Meta-
Morph 7 software.
Glucose uptake assay
C2C12 cells were plated on a 6-well plate coated with 5 ug/ml fibronectin 
(f1141; Sigma-Aldrich). 42 h after transfection (with Lipofectamine 2000), 
cells were washed in warm PBS, starved in DMEM/0.1% BSA for 6 h, and 
washed again. After treatment with 200 nM insulin/PBS (I0516; Sigma- 
Aldrich) for 30 min at 37°C, cells were washed and incubated for 10 min at 
37°C with 1 uCi/ml 2-deoxy-d-[
3H]glucose (NET328A250UC; PerkinElmer) 
and 0.1 mM cold 2-deoxy-d-glucose (D8375; Sigma-Aldrich). 20 nM of cy-
tochalasin B (glucose transport inhibitor; C6762; Sigma-Aldrich) was added 
to control wells. Then, cells were washed in cold PBS, lysed in 0.2 N NaOH 
for 2 h at room temperature, and radioactivity was determined using scintil-
lation fluid.
Statistical analysis and image acquisition
Data are presented as means ± SEM. The statistical significance was deter-
mined with one-tailed paired Student’s t test. Alpha level was set to 0.05. 
Muscle sections were imaged at room temperature with an upright fluores-
cent microscope (model 80i; Nikon) and a monochrome camera (model 
C8484-03; Hamamatsu Photonics), and C2C12 myotubes with an inverted 
motorized microscope (model Ti-E; Nikon) and a cooled CCD camera 
(ORCA-R2; Hamamatsu Photonics). Image acquisition and processing was 
performed using MetaMorph software. Black and white images were pro-
cessed with Photoshop CS3 software, version 10.0.1 (Adobe).
Online supplemental material
Fig. S1 shows that plakoglobin expression (mRNA levels) does not change 
during fasting. Fig. S2 shows the distribution of GFP-plakoglobin in muscle, 
which is similar to the endogenous protein. Fig. S3 shows that overexpres-
sion of Trim32 in normal muscle for 10 d does not induce fiber atrophy and 
does not reduce signaling through the PI3K–Akt pathway. Fig. S4 shows 
that the desmosomal component desmoplakin interacts with plakoglobin in 
skeletal muscle but is not essential for PI3K–Akt–FoxO signaling. Table S1 
lists the qPCR primers and shRNA oligos which were used in the present 
study. Online supplemental material is available at http://www.jcb.org/
cgi/content/full/jcb.201304167/DC1. Additional data are available in 
the JCB DataViewer at http://dx.doi.org/10.1083/jcb.201304167.dv.
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of 20 µg of plasmid DNA into adult mouse TA muscle and application of mild 
electric pulses (12V, 5 pulses, 200-ms intervals; Cohen et al., 2012). In fasting 
experiments food was removed from cages 4 d after electroporation for 48 h. 
Fiber size was determined by measurements of cross-sectional area of 500 
transfected (express GFP) and 500 adjacent nontransfected fibers in the same 
muscle section (10 µm), using MetaMorph software (Molecular Devices).
Antibodies and constructs
The Trim32 and control shRNAs (Cohen et al., 2012), as well as the plako-
globin and desmoplakin shRNA, were designed using Invitrogen’s BLOCK-iT 
RNAi expression vector kit with the pcDNA 6.2-GW/EmGFP-miR vector. The 
GFP-plakoglobin vector was provided by M. Dunach (Autonomous University 
of Barcelona, Barcelona, Spain). The Trim32-DN and Trim32 plasmids (both 
also encode GFP, which allows identification of the transfected fibers) were 
provided by M. Kules-Martin (Oregon Health and Science University, Port-
land, OR), and the HA-Trim32 construct by S. Hatakeyama (Hokkaido Univer-
sity Graduate School of Medicine, Sapporo, Japan). Plakoglobin antibodies 
were from GeneTex and Sigma-Aldrich. Anti-laminin and GAPDH were from 
Sigma-Aldrich. Anti-tubulin was from Invitrogen, and anti-GFP and anti- 
dystrophin from Abcam. The Pax7 antibody was developed by A. Kawakami 
(Tokyo Institute of Technology, Yokohama, Japan) and obtained from the De-
velopmental Studies Hybridoma Bank developed under the auspices of the 
NICHD and maintained by The University of Iowa, Department of Biology 
(Iowa City, IA). Anti-HA, Akt, P-Akt, PI3K–p85, P-PI3K–p85, FOXO3,   
P-FOXO3, insulin receptor, P-insulin receptor (Y1361), p70S6K, and p4E-BP1 
were from Cell Signaling Technology. The desmoplakin antibody was pur-
chased from Santa Cruz Biotechnology, Inc., and the Trim32 antibody was pro-
vided by J. Schwamborn (ZMBE Institute of Cell Biology, Münster, Germany).
Fractionation of muscle tissue
Work was performed at 4°C. Mouse TA muscles were homogenized on ice 
for 30 s in 19 vol of buffer C (20 mM Tris-HCl, pH 7.6, 5 mM EDTA/NaOH, 
pH 7.4, 100 mM KCl, 1 mM DTT, and 1 mM sodium orthovanadate) and 
spun at 2,900 g for 20 min to pellet nuclei and unbroken tissue. The super-
natant was centrifuged at 180,000 g for 90 min and the supernatant (i.e., 
cytosolic fraction) stored at 80°C. The pellet was resuspended in 10 vol of 
buffer M (20 mM Tris-HCl, pH 7.6, 5 mM EDTA/NaOH, pH 7.4, 100 mM 
KCl, 1 mM DTT, 0.25% sodium deoxycholate, 1% NP-40, and 1 mM sodium 
orthovanadate), rotated at 4°C for 20 min, and centrifuged at 100,000 g 
for 30 min. The supernatant (i.e., membrane fraction) was then collected and 
stored at 80°C. All buffers contained protease inhibitors (10 µg/ml leu-
peptin, 3 mM benzamidine, 1 µg/ml trypsin inhibitor, and 1 mM PMSF). 
0.25% of membrane fraction and 0.01% of cytosolic fraction were sepa-
rated on SDS-PAGE for Western blot analysis.
For the immunoblotting and immunoprecipitation experiments, mus-
cles were homogenized in cold extraction buffer (20 mM Tris-HCl, pH 7.2, 
5 mM EGTA, 100 mM KCl, 1% Triton X-100, 10 µg/ml leupeptin, 10 µg/ml 
pepstatin, 3 mM benzamidine, 1 µg/ml trypsin inhibitor, and 1 mM   
PMSF) and incubated at 4°C for 1 h with gentle agitation. After centrifuga-
tion at 3,000 g for 30 min at 4°C, the supernatant (i.e., cytosolic fraction) 
was stored at 80°C. Phosphatase inhibitors were not added to extraction 
buffer except for the immunoprecipitation experiments and blots presented 
in Fig. 5 (1 mM Na3VO4 and 50 mM NaF).
Protein analysis
Immunoblotting and immunoprecipitation were performed as described in 
Cohen et al. (2009). In brief, the cytosolic fraction from TA muscle was used 
for immunoblotting or immunoprecipitation and was resolved by SDS-PAGE 
and immunoblotting with specific antibodies and secondary antibodies con-
jugated to alkaline phosphatase. Immunoprecipitation assays of plakoglobin 
or PI3K–p85 from the soluble fraction of muscle were performed overnight at 
4°C and then protein A/G agarose was added for 4 h.
Quantitative real-time PCR
Total RNA was isolated from muscle and cDNA synthesized by reverse tran-
scription. Real-time qPCR was performed on mouse target genes using spe-
cific primers (Table S1) and DyNAmo HS SYBR Green qPCR kit (F-410S; 
Finnzymes) according to the manufacturer’s protocol.
Immunofluorescence
Immunofluorescence of paraffin-embedded muscle sections was performed 
as reported previously (Cohen et al., 2012). In brief, muscle cross or longi-
tudinal sections from fed and fasted mice were embedded in paraffin and 
then gradually rehydrated in ethanol/PBS. For immunofluorescence of re-
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